Company Description
Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally.
It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes.
The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes.
In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool.
Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software.
Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
| Country | United States |
| Founded | 2008 |
| IPO Date | Dec 11, 2020 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 1,546 |
| CEO | William Feehery |
Contact Details
Address: 4 Radnor Corporate Center, Suite 350 Radnor, Pennsylvania 19087 United States | |
| Phone | 415 237 8272 |
| Website | certara.com |
Stock Details
| Ticker Symbol | CERT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $23.00 |
| CIK Code | 0001827090 |
| CUSIP Number | 15687V109 |
| ISIN Number | US15687V1098 |
| SIC Code | 7372 |
Key Executives
| Name | Position |
|---|---|
| Dr. William F. Feehery Ph.D. | Chief Executive Officer and Director |
| Leif E. Pedersen | President and Chief Commercial Officer |
| John E. Gallagher III | SVice President, Principal Accounting Officer and Chief Financial Officer |
| Dr. Robert P. Aspbury Ph.D. | President of Certara Scientific Software |
| Daniel D. Corcoran | Senior Vice President and General Counsel |
| Ron DiSantis | Senior Vice President of Corporate Development |
| Sheila Rocchio MBA | Chief Marketing Officer |
| Rona Anhalt | Chief Human Resources Officer |
| Dr. Frederic Yves Bois Ph.D., Pharm.D. | Senior Scientific Advisor, Head of Mechanistic Modeling and Member of Simcyp Advisory Board |
| Dr. David Mitchell Ph.D. | Senior Vice President of Strategic Engagement |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2025 | SCHEDULE 13D/A | Filing |
| Apr 14, 2025 | 8-K | Current Report |
| Apr 8, 2025 | ARS | Filing |
| Apr 8, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 8, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2025 | 144 | Filing |
| Mar 28, 2025 | D | Notice of Exempt Offering of Securities |
| Mar 5, 2025 | 8-K | Current Report |
| Feb 26, 2025 | 10-K | Annual Report |
| Feb 26, 2025 | 8-K | Current Report |